Skip to content
Screener

Medtronic MDT Neuroscience — Reportable segment operating profit

Other segment segments

Cardiovascular
$1.07B+11.8%
Medical Surgical
$605M+5.2%
Diabetes
$57M+14.0%
Other operating segment
-$1M-108%

Similar metrics at other companies

California Resources logo
CRCTotal Reportable Segments — Segment profit or (loss)
$270M+12.0%
ARE
AREReportable Segment, Aggregation before Other Operating Segment — Reportable segment net operating income (reportable segment profit or loss)
$413.14M-16.2%
Elevance Health logo
ELVCarelonRx Segment — Reportable segments’ operating gain
$582M+8.6%
Designer Brands logo
DBIRetail — Segment operating profit
$51.28M+28.3%
United Parcel Service, Inc. logo
UPSInternational Segment — Operating profit
$623M-7.3%
LCI Industries logo
LCIIAftermarket Segment — Operating profit
$51.88M+43.6%

Other financials

Income statement

See full
Revenue$9.8B+9.9%
Gross profit$6.4B+10.9%
Operating income$1.9B+30.4%
Net income$1.2B+17.8%
EPS (diluted)$0.97+18.3%

Balance sheet

See full
Cash & equivalents$1.9B-12.1%
Total debt$29.2B-1.6%
Total equity$49.5B+3.0%
Total assets$93.0B+1.5%

Cash flow

See full
Operating cash flow$2.6B+1.8%
CapEx$488.0M+6.3%
Free cash flow$2.1B+0.8%

Valuation

See full
Market cap$110.07B-3.9%
Enterprise value$137.33B-3.2%
P/E22.9×-1.6×
P/S-0.3×

Profitability

See full
Gross margin65%-0.3pp
Operating margin17.8%0.0pp
Net margin13.2%-0.7pp
FCF margin14.9%-0.5pp

Returns & leverage

See full
Return on equity9.8%+0.4pp
Debt / equity0.6×0.0×
Current ratio2.1×+0.3×

Where this comes from

Reported directly by Medtronic in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Medtronic’s 10-K, filed June 18, 2026.

Filed
Jun 18, 2026, 4:27 PM EDT
Fiscal year
FY2026
Accession
0001628280-26-044354
(in millions)CardiovascularNeuroscienceMedical SurgicalTotal
Research and development expense1,1366166862,438
Selling, general, and administrative expense4,5193,4212,51110,451
Other segment items(3)(46)36144
Reportable segment operating profit$3,672$3,062$2,128$8,862
Reconciliation of segment profit / (loss)
Other operating segments profit(1)106
Currency and other(112)
Interest expense, net(715)

Item 8. Financial Statements and Supplementary Data

FAQ

What is Medtronic's neuroscience — reportable segment operating profit?
Medtronic (MDT) reported neuroscience — reportable segment operating profit of $879M in Q1 2026.
How has Medtronic's neuroscience — reportable segment operating profit changed year-over-year?
Medtronic's neuroscience — reportable segment operating profit increased by 2.4% year-over-year, from $858M to $879M.
What is the long-term trend for Medtronic's neuroscience — reportable segment operating profit?
Over 4 years (2022 to 2026), Medtronic's neuroscience — reportable segment operating profit has grown at a -5.6% compound annual growth rate (CAGR), from $3.86B to $3.06B.
What does neuroscience — reportable segment operating profit mean?
This represents the operating income generated by the Neuroscience business segment after deducting direct operating expenses. It serves as a key indicator of the segment's profitability and its contribution to the overall corporate bottom line.

Ask your AI about Medtronic's neuroscience — reportable segment operating profit.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude